17:08 , Oct 26, 2018 |  BC Week In Review  |  Company News

Canbridge, WuXi team up to develop rare disease therapies in China

Canbridge Life Sciences Ltd. (Beijing, China) and WuXi Biologics Inc. (HKSE:2269) partnered to develop rare disease therapeutics in China. Canbridge expects to submit its first IND from the program for a rare disease in China...
19:20 , Oct 23, 2018 |  BC Extra  |  Company News

Canbridge, WuXi team up to develop rare disease therapies in China

Canbridge Life Sciences Ltd. (Beijing, China) and WuXi Biologics Inc. (HKSE:2269) partnered to develop rare disease therapeutics in China. Canbridge expects to submit its first IND from the program for a rare disease in China...
03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
01:40 , Jan 27, 2018 |  BioCentury  |  Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier...
01:27 , Jan 13, 2018 |  BioCentury  |  Strategy

Remapping growth

As patisiran and fitusiran get closer to market, Alnylam Pharmaceuticals Inc. and Sanofi Genzyme concluded that the territorial complexity of their partnership for the products would limit their commercial value. Amendments announced on Jan. 7...
00:05 , May 20, 2017 |  BioCentury  |  Strategy

Henri: N of 1

Gaucher’s disease had swollen Brian Berman’s spleen to the size of a basketball and physicians at NIH told the three-year-old’s parents that it had to be removed. It was 1984, there was no effective treatment...
17:22 , May 15, 2017 |  BC Extra  |  Company News

Orphan drug giant Termeer passes away

Henri Termeer, the former chairman, president and CEO of Genzyme Corp. and one of the handful of individuals who personified the biotech industry in its early decades, passed away May 12 at age 71. Termeer...
07:00 , Mar 28, 2016 |  BioCentury  |  Strategy

Canbridge can-can

Canbridge Life Sciences Ltd .'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its...
07:00 , Jun 8, 2015 |  BioCentury  |  Product Development

Perennial pioneer

Genzyme Corp. aims to remain a leader in Orphan diseases by adopting clinical innovations from oncology and continuing to engage patients from early research all the way to the market to speed development, approval and...
02:24 , Nov 22, 2014 |  BC Extra  |  Company News

Genzyme's Cerdelga gets CHMP nod for Gaucher's

EMA's CHMP recommended marketing authorization of Cerdelga eliglustat tartrate from the Genzyme Corp. unit of Sanofi (Euronext:SAN; NYSE:SNY) to treat Type I Gaucher's disease. Cerdelga is an oral ceramide analog that inhibits glucosylceramide synthase (GCS)....